The purpose of the present technology is to provide: a protein that has a protocatechuic acid 5-position oxidizing activity and can efficiently generate gallic acid from protocatechuic acid; and a microbial strain that expresses said protein. In the present invention, the use of a protocatechuic acid 5-position oxidizing enzyme derived from Comamonas microbes or a protein having at least 70% identity with the amino acid sequence of said protocatechuic acid 5-position oxidizing enzyme allows efficient production of gallic acid from protocatechuic acid. Gallic acid can be produced from protocatechuic acid as a result of fermentation using a microbial strain into which a gene that codes for said enzyme has been introduced.
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nucleic acid construct including a polynucleotide that codes for at least two types of T cell epitopes and a polynucleotide that codes for one or more types of B cell epitopes for the target protein. The present invention makes it possible to powerfully induce antibodies against a target protein within the body of a subject, making it possible not only to induce antibody production against exogenous antigens such as bacteria and viruses but also to induce antibody production against proteins produced within the body of the self.
C12N 15/40 - Protéines de virus à ARN, p.ex. flavivirus
C12N 15/45 - Paramyxoviridae, p.ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
C12N 15/50 - Coronaviridae, p.ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
3.
PRODUCTION METHOD FOR MICROFIBRILLATED CELLULOSE MOLDED ARTICLE, AND MICROFIBRILLATED CELLULOSE MOLDED ARTICLE
This method is for producing a microfibrillated cellulose molded article formed of a microfibrillated cellulose and a phenolic resin. The method for producing a microfibrillated cellulose molded article comprises: a step for preparing a first preliminary molded sheet formed of a microfibrillated cellulose and 0-10 mass% of water; a step for obtaining a second preliminary molded sheet by exposing the first preliminary molded sheet to water for at least one hour to swell the sheet; a step for obtaining a third preliminary molded sheet by replacing the water contained in the second preliminary molded sheet with a solution containing a phenolic resin having a weight-average molecular weight of at most 1000; a step for drying the obtained third preliminary molded sheet; and a step for thermally pressing the dried third preliminary molded sheet by applying a pressure of 1-10 MPa to the sheet in the thickness direction at a temperature of 120-200°C.
D21H 19/24 - Couches sans pigments appliquées sous une forme autre que la solution aqueuse définie dans le groupe comprenant des composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
D21H 11/18 - Fibres hautement hydratées, gonflées ou aptes à être fibrillées
4.
COMPOSITION CONTAINING BOROHYDRIDE SHEET AND CARRIER, AND HYDROGEN RELEASE METHOD USING SAME
The purpose of the present invention is to provide: a composition which is capable of efficiently releasing hydrogen; and a hydrogen release method. The above are achieved by means of a composition which contains a borohydride sheet and a carrier at a volume ratio of 1:0.1 to 100 so that the transmittance of ultraviolet light is more than 0% but less than 100%.
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
C01B 6/00 - Hydrures de métaux; Monoborane ou diborane; Leurs complexes d'addition
C01B 6/11 - Préparation à partir de bore ou de composés inorganiques contenant du bore et de l'oxygène
5.
PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATION CAUSED BY ACANTHAMOEBA
The purpose of the present invention is to provide a pharmaceutical composition and the like for treating or preventing inflammation caused by Acanthamoeba. Specifically provided are a pharmaceutical composition for treating or preventing inflammation caused by Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, an antiprotozoal composition that contains a composite formed by joining lysozyme and chitosan, an anti-attachment agent for Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, and the like.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A contact lens-shaped intraocular lighting device comprising: a contact lens including a dome-shaped first region that is provided in a central portion and through which light is transmitted, a ring-shaped second region that extends outward in a radial direction from an outer peripheral portion of the first region, and a ring-shaped third region that extends outward in the radial direction from an outer peripheral portion of the second region and is provided to be in contact with the sclera; and a lighting unit that is provided in the second region of the contact lens, adjusts refraction or diffusion of light provided from a light source, and emits the light into the eye.
This organ deformation estimation device is provided with: a three-dimensional model acquisition unit which acquires a three-dimensional model that shows the shape of an organ, the three-dimensional model being generated on the basis of a three-dimensional image of the organ which has been captured previously before the implementation of a treatment; a captured image acquisition unit which acquires a captured image that is an image of the inside of the organ which has been captured during the process of the treatment; a partial image extraction unit which extracts a partial image from the three-dimensional image; an alignment unit which performs the alignment of the captured image with the partial image; a target position calculation unit which calculates a target position on the basis of the result of the alignment; and a displacement estimation unit which estimates the deformation of the organ during the process of the treatment by deforming the three-dimensional model on the basis of a three-dimensional simulation in such a manner that the position of a part corresponding to the inside among parts constituting the three-dimensional model is displaced to the target position.
The present invention provides an information processing method, an information processing system, and a computer program. According to the present invention, a computer executes processing that: acquires respective first intermediate representations from a plurality of devices, the first intermediate representations being obtained by applying an intermediate representation conversion function to first data used individually at the devices; acquires respective second intermediate representations from the plurality of devices, the second intermediate representations being obtained by applying the intermediate representation conversion function to second data used in common at the devices; adjusts a parameter for an integrated representation conversion function to minimize the difference in integrated representations obtained by applying the integrated representation conversion function to each of the respective second intermediate representations acquired from the devices; and, on the basis of each of the respective first intermediate representations acquired from the devices and the integrated representation conversion function after adjustment of the parameter, derives a device difference correction function for correcting the device difference between the plurality of devices.
A method for reconstructing an interior CT image in which a region of interest in an object is irradiated with X-rays and an image of the region of interest in a cross section of the object is reconstructed, wherein the method includes: a projection data acquisition step in which a plurality of pieces of projection data are acquired for an occasion on which the region of interest of the object is irradiated with X-rays in a predetermined angular range in the circumferential direction of the object; and an image calculation step in which when matrices holding pixel information for an occasion on which X-rays pass through a cross section of the object in accordance with the irradiation angle serve as projection calculation matrices, a vector in which the plurality of pieces of projection data are arranged is denoted by b, a matrix in which a plurality of the projection calculation matrices corresponding to the projection data are arranged is denoted by A, and a vector in which the image values of the cross section of the object are arranged is denoted by x, Ax = b is solved under prior information C and an image of the region of interest is determined, said prior information C being the sum of the image values of an image of the cross section of the object.
GENE INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR PRODUCING MUSCLE TISSUE AND METHOD FOR PRODUCING EDIBLE MEAT
Provided are: a gene inducing differentiation into fast muscle fibers, said gene being capable of increasing or suppressing the ratio of fast muscle fibers in a muscle tissue and preventing or restoring muscle weakness caused by, for example, aging, injuries or diseases, etc.; a composition for inducing differentiation into fast muscle fibers; a method for inducing differentiation into fast muscle fibers; a method for producing a muscle tissue; and a method for producing an edible meat. A gene inducing differentiation into fast muscle fibers, said gene including a gene encoding a fast muscle fiber differentiation inducing factor comprising any of proteins MafA, MafB and c-Maf; and a composition for inducing differentiation into fast muscle fibers, a method for inducing differentiation into fast muscle fibers, a composition for inhibiting differentiation into fast muscle fibers, a method for inhibiting differentiation into fast muscle fibers, a method for producing a muscle tissue and a method for producing an edible meat, each mainly using the aforesaid gene.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
The purpose of the present invention is to provide a volatile material monitoring system that can accurately acquire the concentration of a volatile material, e.g., ethanol, in an incubator and thereby enable suitable management of the influence exercised by the volatile material on the health of a pediatric patient. The volatile material monitoring system comprises: one or a plurality of sensors (14a, 14b, 14c) disposed in an incubator (1) comprising a housing compartment (101) having a temperature- and humidity-regulatable interior in order to house a pediatric patient (X), wherein the sensor or sensors detect the concentration of a volatile material used due to medical intervention on a pediatric patient (X) in the housing compartment (101); and an estimation unit (161) that estimates, on the basis of the volatile matter concentration detected by the sensors (14a, 14b, 14c), the volatile matter blood concentration in the blood of the pediatric patient (X).
The present invention removes volatile substances from air in an incubator. A purification device (120) includes: an air intake part (121b) for taking in air; a suction part (125) for sucking the air; a second removal part (126) for removing volatile substances, which are substances used in medical intervention on an infant patient, from the air sucked by the suction part (125); and an exhaust part (122b) for exhausting the air from which the volatile substances have been removed by the second removal part (126).
The purpose of the present invention is to avoid the accidental exposure of an infant patient in an infant incubator to a volatile substance. This infant incubator (3) is provided with: a housing chamber (101) in which an infant patient (X) can be housed; and a removal section (134) for removing a volatile substance from air in the housing chamber (101).
F24F 7/003 - Ventilation combinée avec le nettoyage de l'air
F24F 8/158 - Traitement, p.ex. purification, de l'air fourni aux locaux de résidence ou de travail des êtres humains autrement que par chauffage, refroidissement, humidification ou séchage par séparation, p.ex. par filtrage par des moyens chimiques utilisant du charbon actif
14.
VOLATILE SUBSTANCE REMOVAL APPARATUS AND VOLATILE SUBSTANCE REMOVAL METHOD
Provided is a volatile substance removal apparatus capable of sufficiently removing volatile substances such as ethanol floating around a child patient in an incubator. The volatile substance removal apparatus (110, 210, 110A) comprises: a suction unit (115) for suctioning air inside a storage chamber (101) from an intake unit (111c); a removal unit (114, 116) for removing volatile substances contained in the air; an exhaust unit (111d) for exhausting the air from which the volatile substances have been removed by the removal unit (114, 116); and a guide unit (112, 212) for guiding air to the intake unit (111c).
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Higashi Taishi
Motoyama Keiichi
Onodera Risako
Matsumoto Yoshitaka
Abrégé
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclodextrin molecules, a single straight-chain molecule passing through the openings in the plurality of cyclodextrin molecules in a skewer-like manner, and a blocking group which is provided at both ends of the single straight-chain molecule and prevents the cyclodextrin molecules and the straight-chain molecule from separating, wherein at least some of the cyclodextrin molecules bind, via a linker, to boronic acid or a monovalent group derived therefrom.
This image processing device emits light from a light source onto an examined eye through an optical system of a first numerical aperture, and acquires information indicating interference light obtained by detecting interference light between signal light, in which light returning from the examined eye owing to the light emitted thereon is transmitted through an optical system of a second numerical aperture, and reference light, which is a division of light from the light source (S200). A first process (S202) is performed for projecting information indicating the interference light to a four-dimensional frequency aperture that is on a four-dimensional space of the light source frequency and the frequency of light from the examined eye owing to the signal light, and is formed by the optical system of the first numerical aperture and the optical system of the second numerical aperture. A second process (S204) is performed for projecting the projected information to a three-dimensional space.
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
18.
METHOD FOR TREATING PATIENT HAVING UNDERGONE PRE-TRANSPLANTATION PROCESS INVOLVED IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, AND COMPOSITION FOR USE IN SAID METHOD
The present disclosure provides: a method for treating a patient who has undergone a pre-transplantation process involved in hematopoietic stem cell transplantation; and a composition for use in said method. The composition according to the present disclosure contains bone-marrow common progenitor cells.
Provided is a robustness verification device comprising: a similar image identification means that uses a degree of similarity between feature amounts obtained by a feature amount extractor to identify a similar image having a predetermined order position in the degree of similarity to the input image in a candidate image group; an order position count means that counts the order position of the similar image with respect to the input image in the candidate image group when adversarial perturbation is applied to the image; a order position calculation means that calculates the order position of the similar image with respect to the input image in the candidate image group when the adversarial perturbation is not applied to the image; and an order position verification means that verifies whether the order position of the similar image counted by the order position count means is within a prescribed range containing the order position of the similar image calculated by the order position calculation means.
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p.ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
20.
LEARNING DEVICE, LEARNING METHOD, AND RECORDING MEDIUM
This learning device comprises a learning means for performing learning of a feature amount extractor f such that the upper limit and the lower limit of a distance, obtained when the feature amount extractor is used, in a feature space between images become close to the distance.
SCANNING IMAGING DEVICE, INFORMATION PROCESSING DEVICE, METHOD FOR CONTROLLING SCANNING IMAGING DEVICE, METHOD FOR CONTROLLING INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, PROGRAM, AND RECORDING MEDIUM
An ophthalmic examination device 1 according to an embodiment is a scanning imaging device for imaging a sample using optical scanning. The ophthalmic examination device 1 acquires a data set by redundantly collecting data on a sample by the optical scanning using an optical scanner 44, an OCT unit 100, and a control section 210. An image data construction section 220 generates an image set on the basis of the acquired data set. An image selection section 225 selects a plurality of images from the generated image set. An image data processing section 231 executes relative positional adjustment of this image set by applying, to this image set, a plurality of registrations respectively based on the selected plurality of images.
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
22.
FAG E 2 PROTEIN-DEFICIENT FAGOPYRUM PLANT AND USE THEREOF
NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (Japon)
JAPAN INTERNATIONAL RESEARCH CENTER FOR AGRICULTURAL SCIENCES (Japon)
UNIVERSITY OF TSUKUBA (Japon)
KAKE EDUCATIONAL INSTITUTION (Japon)
Inventeur(s)
Hara Takashi
Ishiguro Koji
Otsuka Shiori
Satoh Rie
Matsui Katsuhiro
Suzuki Tatsuro
Yasui Yasuo
Osawa Ryo
Kondo Yasuto
Okamoto Kaoru
Teshima Reiko
Maruyama Kyonoshin
Abrégé
The present invention addresses the problem of providing a Fagopyrum plant having reduced allergen reactivity. In the Fagopyrum plant, the Fag e 2 gene is mutated, and the Fag e 2 protein is deleted. If there is a stop codon mutation in the translation region, it is preferable to have a stop codon mutation so as not to generate a mutant protein having a reduced molecular weight.
NIPPON TELEGRAPH AND TELEPHONE CORPORATION (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Nagata, Masaaki
Wei, Yizhen
Utsuro, Takehito
Abrégé
Provided is an estimation device equipped with: an input unit for inputting an expanded word correspondence for original text and translated text, and a translation quality tag for said original text and said translated text; and an editing tag estimation unit for estimating an editing tag on the basis of the expanded word correspondence and the translation quality tag.
The present invention relates to a pharmaceutical composition for blood cell recovery after allogeneic cord blood transplant, the pharmaceutical composition containing romiplostim as an active ingredient. The pharmaceutical composition is characterized by being administered starting the day after the transplant. The present invention also relates to a method for treating an allogeneic cord blood transplant recipient using the pharmaceutical composition.
Provided is a pavement structure which has good workability and durability and can sustainably draw electricity from an environment such as a facility infrastructure. A pavement structure (1) in which a roadbed layer (2) and a road surface layer (3) supported by the roadbed layer (2) are installed, wherein the roadbed layer (2) comprises a layered part (80) formed by stacking unit structures (81) having a void, and a device part (10) shaped like a box. The device part (10) has a tertiary battery part (30) that generates electricity from variations in electrode temperature and/or a thermoelectric conversion cell part (20) that generates electricity from the difference in temperature between electrodes.
22 in the poly(cysteine) being protected by a hydrophobic alkylcarbonyl, hydrophobic alkylthio, or the like. Also disclosed are self-organizing nanoparticles of such a copolymer and the use of said self-organizing nanoparticles. The copolymer or self-organizing nanoparticles have low toxicity and exhibit efficacy in, e.g., the prevention or treatment of cancer, acute liver injury, inflammatory liver disease, septicemia, or ulcerative colitis through oral administration.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 38/02 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
The present invention improves the quality of sleep. According to the present invention, a control device comprises a determination unit that determines the sleep stage of a subject on the basis of bioinformation for the subject and a control unit that controls a sleep induction device that comprises a beat generation unit that generates binaural beats. The control unit makes the beat generation unit generate binaural beats that have a frequency of less than 1.0 Hz at least during the sleep stages of the subject.
A61M 21/02 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscience; Dispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p.ex. pour mettre en état d'hypnose pour provoquer le sommeil ou la relaxation, p.ex. par stimulation directe des nerfs, par hypnose ou par analgésie
28.
ELECTRON SPIN RESONANCE DEVICE AND DETERIORATION EVALUATION METHOD
This electron spin resonance device comprises a hollow resonator having a microwave oscillator, a magnet, a modulation coil, and an opening. Microwaves generated by the microwave oscillator resonate in the hollow resonator and are emitted from the opening toward an object being measured that is positioned outside of the opening. The magnet applies a magnetic field to an irradiated surface at which the object being measured is irradiated with the microwaves. The modulation coil modulates either the strength of the magnetic field applied to the irradiated surface at which the object being measured is irradiated with the microwaves, or the frequency of the microwaves.
G01N 24/10 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance paramagnétique électronique
Provided is an assistance device which can independently control assistance with knee bending/extending actions and assistance with upper body posture. The assistance device comprises a base, a first link fixed to the base, a second link rotatably linked to the first link, a third link rotatably linked to the second link, and an elastic connection part incorporated between the third link and a prescribed position on the first link or the base.
This medical imaging equipment has an illumination unit 11 for spot-illuminating the center of a surgical field of a surgery patient, a surgical field camera unit 12 for imaging the center of the range irradiated by the illumination unit 11, a casing 13 for covering the illumination unit 11 and the surgical field camera unit 12, and a pair of display units 14, 14 that can be viewed from both sides of the surgery patient.
A61B 90/30 - Dispositifs pour éclairer une zone chirurgicale, les dispositifs ayant une corrélation avec d’autres dispositifs chirurgicaux ou avec une intervention chirurgicale
H04N 23/53 - Caméras ou modules de caméras comprenant des capteurs d'images électroniques; Leur commande - Détails de structure de viseurs électroniques, p. ex. rotatifs ou détachables
H04N 23/56 - Caméras ou modules de caméras comprenant des capteurs d'images électroniques; Leur commande munis de moyens d'éclairage
31.
COMBINATION THERAPY INVOLVING RADIOTHERAPY AND HYPOXIA-RESPONSIVE PRODRUG OF ANTICANCER DRUG, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG
In the present invention, an anticancer drug/prodrug is used in a combination therapy with radiotherapy. In the chemical formula representing the same, the moiety in which R1 and R2 are bonded to an N atom results from the removal of an amino group or an imino group from an anticancer drug (selected from the group consisting of, e.g., gemcitabine, niraparib, crizotinib, dabrafenib, vemurafenib, entinostat, cobimetinib, palbociclib, and ribociclib) having the amino group or the imino group. Adverse effects from the effect of treating malignant tumors using radiotherapy are thereby reduced, or the effect of the treatment is enhanced.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4406 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 3, p.ex. zimeldine
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/4523 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by formulas (1) to (23). This pharmaceutical composition for treating hypertriglyceridemia contains the aforementioned SREBP-1 inhibitor and a pharmacologically acceptable carrier.
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide non condensés avec un autre cycle, p.ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p.ex. cromakalim
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p.ex. carbazole
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p.ex. ticlopidine
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4535 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p.ex. pizotifène
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
C07D 209/88 - Carbazoles; Carbazoles hydrogénés avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du système cyclique
C07D 231/44 - Atomes d'oxygène et d'azote ou atomes de soufre et d'azote
C07D 333/38 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro- dans lesquels le système condensé contient au moins quatre hétérocycles
One aspect of the present invention is a humanized anti-DNAM-1 antibody or an antigen-binding fragment thereof, having: a heavy chain variable region comprising an amino acid sequence represented by SEQ ID NO: 1, serving as HCDR1, an amino acid sequence represented by SEQ ID NO: 2, serving as HCDR2, and an amino acid sequence represented by SEQ ID NO: 3, serving as HCDR3; and a light chain variable region comprising an amino acid sequence represented by SEQ ID NO: 4, serving as LCDR1, an amino acid sequence represented by SEQ ID NO: 5, serving as LCDR2, and an amino acid sequence represented by SEQ ID NO: 6, serving as LCDR3.
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
34.
ESTABLISHMENT OF THERAPY AND DIAGNOSIS FOR ALLERGIC DISEASES THROUGH CONTROL OF IMMUNOGLOBULIN-BINDING PROTEIN
KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
METAGEN, INC. (Japon)
Inventeur(s)
Fukuda Shinji
Nakato Gaku
Obana Nozomu
Furukawa Risako
Abrégé
The present invention addresses the problem of revealing a symptom onset mechanism of allergies in which bacteria belonging to the family Lachnospiraceae including Ruminococcus gnavus (R. gnavus) which is an enteric bacterium is involved, and developing a means for preventing or treating allergies by intervening in the mechanism. As a result of conducting thorough investigation, the present inventors have found that Ibp protein from bacteria belonging to the family Lachnospiraceae is involved in the onset of allergies, and have shown that said problem can be solved. Specifically, it is possible to prevent allergic reactions occurring in a body by administering, to the body, or inducing production of, within the body, a substance that binds to Ibp protein from bacteria belonging to the family Lachnospiraceae.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
Provided is a measuring device comprising on a substrate, for example: N (N is an integer of 1 or more) first terminals respectively electrically connected to a maximum of M (M is an integer of 1 or more) anodes; and M second terminals respectively electrically connected to a maximum of N cathodes, wherein each of the anodes is electrically connected to one of the first terminals, each of the cathodes is electrically connected to one of the second terminals, M and/or N is 2 or more, when M is 2 or more, the anode and the corresponding cathode electrically connected to the same first terminal are electrically connected to different second terminals, and when N is 2 or more, the cathode and the corresponding anode electrically connected to the same second terminal are electrically connected to different first terminals.
G01N 27/27 - Association de plusieurs systèmes ou cellules de mesure, chacun mesurant un paramètre différent, dans laquelle les résultats des mesures peuvent être, soit utilisès indépendamment, les systèmes ou les cellules étant physiquement associés, soit combin
G01N 27/404 - Cellules avec l'anode, la cathode et l'électrolyte de la cellule du même côté d'une membrane perméable qui les sépare du fluide de l'échantillon
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
TAIYO SERVICE INC. (Japon)
Inventeur(s)
Iwata, Yasushi
Matsui, Hirofumi
Suzuki, Iwane
Suzuki, Yuji
Tomita, Kanako
Yang, Tianjing
Ikeda, Takafumi
Kurokawa, Hiromi
Abrégé
Provided is an anticancer agent containing nitrogen 15 and also containing a substance that is accumulated specifically in cancer cells. Also provided is a method for killing cancer cells in vitro, said method comprising accumulating nitrogen 15 in cancer cells in vitro and irradiating the cancer cells with proton beams in vitro. Also provided is a cancer therapy method comprising accumulating nitrogen 15 in cancer cells of a human or a non-human animal and irradiating the human or non-human animal with proton beams.
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 31/197 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p.ex. acide gamma-aminobutyrique (GABA), bêta-alanine, acide epsilon-aminocaproïque, acide pantothénique
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61N 5/10 - Radiothérapie; Traitement aux rayons gamma; Traitement par irradiation de particules
This intraocular illumination device comprises: a fiber for guiding light from a light source; and a holder which is disposed between an objective lens of a microscope and an eye during surgery or inspection of the eye and which supports the leading end of the fiber. Provided to the leading end of the fiber is a reflective part on which the light guided through the fiber is reflected toward the interior of the eye.
By using this therapeutic device (1) which is characterized in that a shape of a target (30) is estimated using an identifier (61) trained on the basis of a first image (23) in which subject in vivo information is captured, a second image (30) showing the target (63) in vivo, and a third image (20) capturing the same subject using a different device from the first image (23), it is possible to accurately estimate the shape of a target treatment area when carrying out training on the shape of a target treatment area using a DRR image processed from a CT image.
This information processing device comprises a reception unit for receiving a plurality of OCT images captured under different imaging conditions and represented by complex signals, an image processing unit for performing digital refocusing by complex signal processing or digital aberration correction by complex signal processing for each of the plurality of OCT images received by the reception unit, and a synthesis unit for synthesizing the plurality of OCT images subjected to digital refocusing by complex signal processing or digital aberration correction by complex signal processing by the image processing unit.
The present invention addresses the problem of increasing backup force that is exerted when a medical device is introduced into a bifurcation while reducing the possibility of vascular damage that may occur when the medical device approaches the bifurcation. An introduction aid (11, 31, 51) for use when a medical device (catheter 22) is introduced into a bifurcation (B) of a blood vessel (aorta A) comprises: a tube (outer sheath 111, 311, 511) having a first passage (P1) that extends from a proximal end (11P, 31P) to a distal end (11E, 31E) having a tapered shape and a second passage (P2) that extends from the proximal end (11P, 31P) to a side hole (Hs); and a flexible inner tube (inner sheath 115, 515) that is introduced into the second passage from the proximal end, with a tip end thereof reaching the side hole. A portion of the inner tube near the tip end is continuously and smoothly bent so that no step is created when the inner tube is not introduced into the second passage.
This structure estimation program causes a computer to perform a proximity data acquisition function to acquire proximity data, which is data relating to whether an element that is included in a object having a one-dimensional sequence and that makes up said one-dimensional sequence is at a distance less than or equal to a prescribed distance from another element of the one-dimensional sequence, and a reconstruction function to reconstruct the proximity data and generate rough structure data indicating the structure of the object, use a nearby point in the structure of the object as indicated by the rough structure data to generate first structure data indicating the structure of the object at a higher spatial resolution than the rough structure data, and use a nearby point in the structure of the object as indicated by the first structure data to generate second structure data indicating the structure of the object at a higher spatial resolution than the first structure data.
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
42.
SEMICONDUCTOR APPARATUS AND METHOD FOR MANUFACTURING SEMICONDUCTOR APPARATUS
This semiconductor apparatus has a substrate film and a semiconductor film formed on the substrate film, wherein the substrate film comprises a polyimide obtained by condensation polymerization of an aromatic diamine and an aromatic tetracarboxylic acid anhydride and has a tensile elasticity in the longitudinal direction of 7 GPa or more, and the semiconductor film is polycrystalline and comprises crystal particles having an average particle size of 1 μm or more.
H01L 21/20 - Dépôt de matériaux semi-conducteurs sur un substrat, p.ex. croissance épitaxiale
C08G 73/10 - Polyimides; Polyester-imides; Polyamide-imides; Polyamide-acides ou précurseurs similaires de polyimides
H01L 21/336 - Transistors à effet de champ à grille isolée
H01L 27/12 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des éléments de circuit passif intégrés avec au moins une barrière de potentiel ou une barrière de surface le substrat étant autre qu'un corps semi-conducteur, p.ex. un corps isolant
This method for producing a carbon nanotube strand wire includes: a first step in which a carbon-containing gas is supplied from one first end section of a tubular carbon nanotube synthesis furnace and a carbon nanotube is grown from each of a plurality of catalyst particles in a suspended state inside the carbon nanotube synthesis furnace to thus synthesize a plurality of carbon nanotubes; a second step in which the plurality of carbon nanotubes are assembled by aligning along the length direction of the carbon nanotubes in a first flow channel provided inside the carbon nanotube synthesis furnace to thus form a carbon nanotube strand wire; and a third step in which the carbon nanotube strand wire is recovered from a second end section, which is opposite to the first end section, of the carbon nanotube synthesis furnace, using a recovery gas flow that flows in a direction of separation from the carbon nanotube synthesis furnace.
C01B 32/164 - Préparation faisant intervenir des procédés continus
D01F 9/10 - Filaments, ou similaires, faits par l’homme, formés d’autres substances; Leur fabrication; Appareils spécialement adaptés à la fabrication de filaments de carbone de matière inorganique par décomposition de substances organiques
44.
METHOD FOR PRODUCING CARBON NANOTUBE STRAND WIRE AND CARBON NANOTUBE STRAND WIRE PRODUCTION DEVICE
As a method for producing a carbon nanotube strand wire capable of efficiently producing a carbon nanotube strand wire in a tubular carbon nanotube synthesis furnace, a gas flow for adhesion suppression is generated from a gas for adhesion suppression release port located between the second end of the carbon nanotube synthesis furnace (side on which carbon nanotube strand wire is recovered) and the end in the heating device on the second end side in a direction from the second end toward the first end (side on which carbon-containing gas is supplied) between the inner wall of the carbon nanotube synthesis furnace and the outer wall of a first flow path for orienting carbon nanotubes to form a carbon nanotube strand wire to suppress the adhesion of a plurality of carbon nanotubes to the inner walls of the carbon nanotube synthesis furnace.
The present invention provides a novel copolymer which is able to be used as a marking agent for a specific part of a biological tissue, and which is also able to be used as a photosensitizer that is topically administered in PDT therapy. A copolymer which comprises a repeating unit represented by formula (I) and a repeating unit represented by formula (II).
C08F 220/60 - Amides contenant de l'azote en plus de l'azote de la fonction carbonamide
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
[Problem] To provide an underwater positioning system and method capable of accurate underwater positioning. [Solution] The underwater positioning system 1 in which at least one among one or more transmitters 2 and one or more receivers 3 is provided at known coordinates, and which positions an unknown point of unknown coordinates in which another transmitter 2 or receiver 3 is provided, comprises: a time window DB 4 that, when unknown points are set within a plurality of regions R set by dividing an underwater positioning range, stores in advance for each region R, a time window for sound waves emitted from the transmitter 2 to reach the receiver 3; and a coordinate estimation/specification unit 6 that calculates, for each region R, a time-windowed impulse response, which is an inner product of the time window and an impulse response of a sound wave propagation path from the transmitter 2 to the receiver 3, and estimates that the unknown point is located in the region R where the energy of the time-windowed impulse response is at maximum.
nn (wherein n ≥ 4, provided that n is an integer); and an electron donor. At least some of the electron donor is supported by the borohydride-containing sheet; electrons of the electron donor are supplied to the borohydride-containing sheet by external stimuli; and hydrogen is generated from the borohydride-containing sheet into which the electrons have been injected.
C01B 6/00 - Hydrures de métaux; Monoborane ou diborane; Leurs complexes d'addition
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p.ex. de l'ammoniac
H01M 8/065 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux par déshydruration de substances métalliques
48.
COMPOSITION FOR PREVENTING OR TREATING TISSUE AGING
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Namihira, Masakazu
Hayashi, Yoshiki
Abrégé
Provided is a composition for preventing or treating tissue aging which contains an S-adenosylmethionine synthase inhibitor. Also provided is a method for screening an anti-aging substance, the method comprising (1) a step for culturing fibroblasts in the presence of a candidate compound, (2) a step for evaluating the propagating capability of the fibroblasts, and (3) a step for quantitatively determining the S-adenosylmethionine in the fibroblasts.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/25 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des enzymes qui ne peuvent pas être classées dans les groupes
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
49.
FLYING OBJECT CONTROL SYSTEM, FLYING OBJECT CONTROL METHOD, AND PROGRAM
Provided is a flying object control system comprising an area-forming part that forms a prescribed area relative to a grip, a detection unit that detects a displacement of the prescribed area formed by the area-forming part, and a control unit that controls the flight of a flying object on the basis of the displacement of the prescribed area detected by the detection unit.
B64C 13/20 - Dispositifs amorçant la mise en œuvre actionnés automatiquement, p.ex. répondant aux détecteurs de rafales utilisant des émissions de signaux
B64C 39/02 - Aéronefs non prévus ailleurs caractérisés par un emploi spécial
G05D 1/00 - Commande de la position, du cap, de l'altitude ou de l'attitude des véhicules terrestres, aquatiques, aériens ou spatiaux, p.ex. pilote automatique
G05D 1/10 - Commande de la position ou du cap dans les trois dimensions simultanément
[Problem] To provide a valproic acid derivative for improving the disadvantages or faults associated with using valproic acid itself as medicine. [Solution] Provided is a polymeric compound of valproic acid that is a block copolymer containing a poly(ethylene glycol) segment and a poly(valproic acid vinyl) segment.
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
The purpose of the present invention is to provide an excellent method for storing and transporting hydrogen. The structural body according to the present invention includes boron, hydrogen and oxygen, and has a B-H-B bond, a B-H bond, and a B-OH bond. When an FT-IR spectrum is measured, the structural body satisfies formula (1) 0.80≤a/c≤0.96 and formula (2) 0.95≤b/c≤1.12 (in the formulae, a represents the transmission rate at 1400 cm-1in the FT-IR spectrum, b represents the transmission rate at 2500 cm-1in the FT-IR spectrum, and c represents the transmission rate at 3200 cm-1 in the FT-IR spectrum).
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p.ex. de l'ammoniac
C01B 6/04 - Hydrures des métaux alcalins, des métaux alcalino-terreux, du béryllium ou du magnésium; Leurs complexes d'addition
C01B 6/10 - Monoborane; Diborane; Leurs complexes d'addition
This cold sensation presentation device comprises: a cold stimulation unit that applies a cold stimulus to a skin in a noncontact manner; a warm stimulation unit that applies a warm stimulus to the skin in a noncontact manner; and a control unit that presents a cold sensation by making different from each other a change over time in intensity of the cold stimulus in a cold stimulation state in which the intensity of the warm stimulus is relatively low and a change over time in intensity of the warm stimulus in a warm stimulation state in which the intensity of the warm stimulus is relatively high and by repeating the cold stimulation state and the warm stimulation state in a state in which the intensity of the cold stimulus is maintained constant.
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
53.
POLY(ETHYLENE GLYCOL)-b-POLY(4-NYLON) AND NANOPARTICLES THEREOF
[Problem] To provide a novel drug delivery system for γ-aminobutyric acid (GABA). [Solution] A block copolymer containing a poly(ethylene glycol) (or PEG) segment and a poly(GABA) (or Nylon 4) segment, and nanoparticles of the block copolymer. The nanoparticles are useful for preventing or treating depression.
The information processing device of the embodiment is provided with: a learning section that carries out learning of a machine learning model that inputs one or more non-polarized OCT images, which do not have polarization information and outputs pseudo-polarized OCT images that correspond to polarized OCT images, which have polarization information; and a storage unit for storing the learning results of the learning section.
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
This strain sensor for detecting surface strain comprises: a soft structure part provided with a pliable sheet and a plurality of protrusions having a prescribed height in a prescribed direction of the sheet, the protrusions being disposed with prescribed spacing on the sheet; and a strain gauge having a plurality of contact parts that respectively come into contact with the tops of the plurality of protrusions, the strain gauge deforming in conformance with changes in the spacing between the peaks caused by deformation of the sheet, and generating a change in electrical characteristics that corresponds to the deformation.
G01B 7/16 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer les déformations dans un solide, p.ex. au moyen d'une jauge de contrainte à résistance
56.
PROPHYLACTIC OR THERAPEUTIC AGENT FOR ALLERGIC DISEASES
[Problem] The present invention addresses the problem of discovering a molecule that is selectively expressed in mast cells and providing a prophylactic or therapeutic agent for allergic diseases. [Solution] This prophylactic or therapeutic agent is for allergic diseases and comprises an anti-Clec12b antibody or an antibody fragment thereof.
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention provides a method for inducing a hibernation-like state and a device therefor. The present invention provides a method for reducing a theoretically set temperature for the body temperature of a subject and/or a feedback gain of heat production in the subject or a method for inducing a hibernation-like state in the subject, said method being a chemical and physical method that comprises applying an excitatory stimulation to a pyroglutamylated RF-amide peptide (QRFP) producing-neuron. The present invention also provides a device to be used for performing this method.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61B 5/01 - Mesure de la température de parties du corps
A61B 5/083 - Mesure du taux de métabolisme en utilisant un essai respiratoire, p.ex. mesure du taux de consommation d'oxygène
58.
METHOD FOR PRODUCING CARBON NANOTUBE STRAND WIRE AND CARBON NANOTUBE STRAND WIRE PRODUCTION DEVICE
The method for producing a carbon nanotube strand wire of the present disclosure is a method for producing a carbon nanotube strand wire provided with a first step for growing carbon nanotubes from each of a plurality of catalyst particles by supplying carbon-containing gas to a plurality of suspended catalyst particles within a tubular carbon nanotube synthesis furnace to obtain a plurality of carbon nanotubes and a second step for aggregating the plurality of carbon nanotubes to obtain a plurality of carbon nanotube strand wires, in which the second step is provided with a step 2A for orienting and aggregating a first carbon nanotube group composed of some of the plurality of carbon nanotubes along the longitudinal direction of the carbon nanotubes within a first flow path to obtain a first carbon nanotube strand wire and a step 2B for orienting and aggregating a second carbon nanotube group composed of some of the carbon nanotubes different from the plurality of carbon nanotubes that compose the first carbon nanotube group along the longitudinal direction of the carbon nanotubes within a second flow path to obtain a second carbon nanotube strand wire.
This apparatus (1) comprises at least one intravascular device (10), (20) that is disposed in a blood vessel of an organism and that is equipped with at least one electrode (11), (12), (21), (22) for detecting or stimulating the activity of nerve tissue positioned outside the blood vessel nearby, the electrodes (11), (12), (21), (22) being provided on a wire member.
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61B 5/293 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
60.
BODY TEMPERATURE LOWERING AGENT, BODY TEMPERATURE ELEVATION SUPPRESSOR, FOOD COMPOSITION FOR LOWERING BODY TEMPERATURE, AND FOOD COMPOSITION FOR SUPPRESSING BODY TEMPERATURE ELEVATION
A body temperature lowering agent, a body temperature elevation suppressor, a food composition for lowering body temperature and a food composition for suppressing body temperature elevation, each comprising, as an active ingredient, at least one substance selected from the group consisting of orotic acid, a derivative thereof and a salt of the same.
To increase the data processing quantity per unit time while reducing the size of circuit structure for transfer control compared with the conventional structure of a combination of logic gates, a first logic circuit (61) of a transfer control element (54) outputs a first output signal (q1) on the basis of an upstream transfer request signal (s1), a reset signal (r1), a first feedback signal (pq1), and a first lookup table, a logic gate (62) outputs an output signal (s2) obtained by applying the logical NOR operation to the upstream transfer request signal (s1), the inverted signal of the first output signal, a second feedback signal (pq2), and a downstream transfer enabling signal (acki), and a second logic circuit outputs a second output signal (q2) on the basis of the output signal (s2) obtained by the logical NOR operation, a downstream transfer enabling signal (r2), the second feedback signal (pq2), and a second lookup table.
The purpose of the present invention is to more accurately evaluate the degree of stability of the posture of a subject. In the present invention, a dependency calculation method (S100) includes: a step (S101) for measuring a first center-of-gravity fluctuation that is a fluctuation, within a first state, in the center of gravity of a subject standing on an elastic member; a step (S102) for measuring a second center-of-gravity fluctuation that is a fluctuation, within a second state, in the center of gravity of the subject standing on the elastic member; and a step (S103) for evaluating the degree of stability of the posture of the subject on the basis of the first center-of-gravity fluctuation and the second center-of-gravity fluctuation. The first state is a state in which the subject sees the surroundings, and the second state is a state in which the subject cannot see the surroundings.
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
63.
FIBROIN MICRO-SPHERE AND METHOD FOR PRODUCING SAME
The present invention provides a method for producing natural polymer micro-spheres, the method comprising: a step for adding an organic solvent having a surfactant dissolved therein to a solution (e.g., fibroin aqueous solution) containing a natural polymer, and homogenizing the obtained mixture to generate a natural polymer colloidal suspension; and a step for adding the natural polymer colloidal suspension to an alcohol having 3 or more carbon atoms to form natural polymer micro-spheres.
The present invention provides a novel drug for the prevention or treatment of coronavirus infections. The present invention relates to a pharmaceutical composition that contains a substance capable of forming a complex with an estrogen receptor and that is for preventing or treating coronavirus infections.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p.ex. œstrane, œstradiol
A61K 31/566 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p.ex. œstrane, œstradiol ayant un groupe oxo en position 17, p.ex. œstrone
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p.ex. fosfosal, dichlorvos, malathion
A61P 31/14 - Antiviraux pour le traitement des virus ARN
This naked-eye stereoscopic image display device comprises: an image display unit that displays a right-eye image and a left-eye image on a transmission-type image display surface in a time division manner; a projection unit that, with a plurality of point light sources which are arranged on an illumination arrangement face in a matrix shape and which turn on/off according to the time division, projects illumination light to the image display surface from the back face of the image display surface; and a light-collecting system array unit which includes a plurality of elemental light-collecting system regions arranged in a planar shape. The light-collecting system array unit is disposed between the image display surface and the illumination arrangement face. The distance between the light-collecting system array unit and the illumination arrangement face is approximately equal to the focal distance of the elemental light-collecting system regions. The light-collecting system array unit includes a common region, which is a region in which portions of adjacent elemental light-collecting system regions coexist, in a region extending from near the centers of the adjacent elemental light-collection system regions to near the boundary therebetween.
H04N 13/32 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des fenêtres en mouvement ou des sources lumineuses en mouvement
G02B 3/08 - Lentilles simples ou composées à surfaces non sphériques à surfaces discontinues, p.ex. lentille de Fresnel
G02B 30/29 - Systèmes ou appareils optiques pour produire des effets tridimensionnels [3D], p.ex. des effets stéréoscopiques en fournissant des première et seconde images de parallaxe à chacun des yeux gauche et droit d’un observateur du type autostéréoscopique comprenant des réseaux lenticulaires caractérisés par la géométrie du réseau lenticulaire, p.ex. réseaux en biais, réseaux irréguliers ou réseaux de formes ou de tailles variables
66.
ENDOSCOPIC DIAGNOSIS ASSISTANCE METHOD AND ENDOSCOPIC DIAGNOSIS ASSISTANCE SYSTEM
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Nosato Hirokazu
Kochi Yuta
Sakanashi Hidenori
Murakawa Masahiro
Ikeda Atsushi
Abrégé
Provided is an endoscopic diagnosis assistance method with which it is possible to clearly distinguish a tested region from an untested region. After a preparatory step S1 for an observation canvas is performed in advance, a frame marking step S2, a key point calculation step S3, a front-back frame displacement calculation step S4, and a front-back marking step S5 are executed so as to record observations. In an image diagnosis assistance step IDS, assistance is provided for image diagnosis to determine whether or not there is a pathological lesion in an organ on the basis of: multiple position data sets obtained by adding markings to observation canvas data for multiple frames; and endoscopic images in the respective frames.
The purpose of the invention of the present application is to provide an image display device and an image display method which enable more natural stereoscopic vision in naked eye stereoscopic vision. An image display device (1) comprises: a plurality of display elements that are arranged in a matrix on a transmission-type image display surface (D1); a plurality of illumination arrangement control elements arranged in a matrix on an illumination arrangement surface (D2) for variably controlling the arrangement of illumination light rays to be projected onto the image display surface; lenses (L1, L2) that generate a real image of the illumination arrangement surface; and a control unit that controls the display elements on the basis of parallax image data, and causes any of illumination light rays of three colors to be projected onto the image display surface by any of the plurality of illumination arrangement control elements on the basis of predetermined time division with each predetermined size matrix of the plurality of illumination arrangement control elements as a unit. In the time division, three colors are respectively assigned to three out of the illumination arrangement control elements included in the matrix in each frame of the time division, and in each period of the time division, the three colors are respectively assigned once to the illumination arrangement control elements included in the matrix.
G09G 3/20 - Dispositions ou circuits de commande présentant un intérêt uniquement pour l'affichage utilisant des moyens de visualisation autres que les tubes à rayons cathodiques pour la présentation d'un ensemble de plusieurs caractères, p.ex. d'une page, en composant l'ensemble par combinaison d'éléments individuels disposés en matrice
G09G 3/34 - Dispositions ou circuits de commande présentant un intérêt uniquement pour l'affichage utilisant des moyens de visualisation autres que les tubes à rayons cathodiques pour la présentation d'un ensemble de plusieurs caractères, p.ex. d'une page, en composant l'ensemble par combinaison d'éléments individuels disposés en matrice en commandant la lumière provenant d'une source indépendante
G09G 3/36 - Dispositions ou circuits de commande présentant un intérêt uniquement pour l'affichage utilisant des moyens de visualisation autres que les tubes à rayons cathodiques pour la présentation d'un ensemble de plusieurs caractères, p.ex. d'une page, en composant l'ensemble par combinaison d'éléments individuels disposés en matrice en commandant la lumière provenant d'une source indépendante utilisant des cristaux liquides
G02B 30/00 - Systèmes ou appareils optiques pour produire des effets tridimensionnels [3D], p.ex. des effets stéréoscopiques
H04N 13/32 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des fenêtres en mouvement ou des sources lumineuses en mouvement
According to the present invention, forward/rearward movement of the center of gravity of a user is suppressed with a simple configuration without supplying power, and thus the user is stably supported before and after posture transition between a standing position and a sitting position. The stable support mechanism comprises: a base; a support which may be mounted on the base to be translated along a first axis in a plane horizontal to the base and of which a posture is changed between a first position and a second position in a plane perpendicular to the base; and a length-fixed link which has one end connected to the base and the other end connected to the support and guides the support in a direction along the first axis as the posture of the support changes.
This feature amount selection device comprises: a feature amount data acquisition unit which acquires feature amount data including, for each of a plurality of samples, pairs of values of a plurality of feature amounts for the samples; a principal component analysis unit which performs, on the feature amount data, principal component analysis in a sample space that is a group of the plurality of feature amounts of the value pairs for each of the plurality of samples of the feature amounts; and a feature amount selection unit which selects a feature amount from among the plurality of feature amounts on the basis of the principal component analysis result performed by the principal component analysis unit.
A secure computation system comprising secure computation server devices, each of which includes: a determination share generation unit that calculates, from a combination of a share representing an index pertaining to an input and a possible index share of an array, a determination share configured so that the index pertaining to the input is a specific value; a combination configuration unit that configures a combination of an array element share and a determination share with respect to the entirety of combinations of possible indexes of the array; a shuffle unit that shuffles the combination; a recovery unit that recovers the determination share in the shuffled combination; and a selection unit that selects the array element share in the combination in which the recovered value is the specific value.
G09C 1/00 - Appareils ou méthodes au moyen desquels une suite donnée de signes, p.ex. un texte intelligible, est transformée en une suite de signes inintelligibles en transposant les signes ou groupes de signes ou en les remplaçant par d'autres suivant un systèm
71.
COPOLYMER CONTAINING POLY(ETHYLENE GLYCOL) AND POLY(L-AMINO ACID DERIVATIVE), MICROPARTICLES THEREOF, AND USE THEREFOR IN PHARMACEUTICAL COMPOSITION
[Problem] The present invention addresses the problem of providing an ornithine assembly that has low toxicity, is effective even when administered orally, and has high bioavailability. In addition, the present invention addresses the problem of providing an ornithine assembly that effectively prevents or treats hepatopathy. [Solution] Provided is a condensate in which an acyl group was introduced to an ornithine side chain amino group of a polyethylene glycol-b-polyornithine, and further provided is a novel assembly that is not based on a PIC.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C08G 65/333 - Polymères modifiés par post-traitement chimique avec des composés organiques contenant de l'azote
72.
INSPECTION LOCATION FIXING TOOL, INSPECTION LOCATION FIXING METHOD, MEDICAL IMAGE CAPTURING SYSTEM, METHOD FOR FABRICATING MEDICAL IMAGE, AND METHOD FOR DISPLAYING MEDICAL IMAGE
This inspection location fixing tool (10) fixes a scrotum (101) or a phallus (102) which are inspection locations of a subject in a prone position when capturing a medical image, the inspection location fixing tool (10) comprising an upper support base (11), a coil base (12), and a lower support base (13) in order on a horizontal surface, wherein the height of the coil base (12) is less than the height of the upper support base (11) and the lower support base (13), and the coil base (12) can be moved vertically. Consequently, this inspection location fixing tool is capable of efficiently fixing the inspection location in medical image capturing, and a medical image of high precision can be provided.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
This image display device displays a stereoscopic image by using a parallax barrier scheme, the image display device comprising: a transmission-type image display surface on which an image having left-eye image data and an image having right-eye image data are alternately displayed; an image forming unit in which a plurality of optical members having a plurality of band-shaped patterns with optical properties are disposed on a surface positioned on the rear surface side of the image display surface; and a plurality of band-shaped light sources which are disposed on a lighting arrangement surface, which is a surface positioned on the rear surface side of the image forming unit, and which irradiate the image display surface with illumination light. Slit regions of a parallax barrier scheme are formed by an image obtained by the optical members of the image forming unit forming an image on the rear surface side of the image display surface with the illumination light from the band-shaped light sources.
G02B 30/31 - Systèmes ou appareils optiques pour produire des effets tridimensionnels [3D], p.ex. des effets stéréoscopiques en fournissant des première et seconde images de parallaxe à chacun des yeux gauche et droit d’un observateur du type autostéréoscopique comprenant des barrières de parallaxe comprenant des barrières actives de parallaxe
G02B 30/33 - Systèmes ou appareils optiques pour produire des effets tridimensionnels [3D], p.ex. des effets stéréoscopiques en fournissant des première et seconde images de parallaxe à chacun des yeux gauche et droit d’un observateur du type autostéréoscopique comprenant des sources de lumière directionnelle ou des sources de rétroéclairage
H04N 13/305 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des lentilles lenticulaires, p.ex. dispositions de lentilles cylindriques
H04N 13/312 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des barrières de parallaxe les barrières de parallaxe étant situées derrière l’affichage, p.ex. entre la source de rétroéclairage et le modulateur spatial de lumière [MSL]
H04N 13/315 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des barrières de parallaxe les barrières de parallaxe variant dans le temps
An electrode 10 comprises, as a catalyst, an alloy which is composed of at least three base metal elements, wherein the atomic composition percentages of the at least three base metal elements are approximately equal, and the at least three base metal elements form a solid solution. In addition, an electrode 12 has: a carbon fiber; and a catalyst in which at least a portion of elements is chemically bonded to the carbon fiber and which comprises a base metal. In addition, a water electrolyzer comprises an anode, a cathode, and a solid polymer electrolyte membrane provided between the anode and the cathode, wherein the anode is the electrode 10, and/or the cathode is the electrode 12.
C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
C25B 9/00 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Éléments de structure des cellules; Assemblages d'éléments de structure, p.ex. assemblages d'électrode-diaphragme; Caractéristiques des cellules relatives aux procédés
C25B 11/073 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par le matériau Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique
H01M 4/90 - Emploi de matériau catalytique spécifié
75.
STRUCTURE, METHOD FOR PRODUCING STRUCTURE, AND ELECTROCHEMICAL DEVICE
C25D 5/18 - Dépôt au moyen de courant modulé, pulsé ou inversé
H01M 4/86 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes inertes ayant une activité catalytique, p.ex. pour piles à combustible
H01M 4/96 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes inertes ayant une activité catalytique, p.ex. pour piles à combustible Électrodes à base de carbone
H01M 8/16 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible biochimique, c. à d. éléments dans lesquels des micro-organismes agissent comme catalyseurs
B32B 7/025 - Propriétés électriques ou magnétiques
C12N 9/06 - Oxydoréductases (1.), p.ex. luciférase agissant sur des composés contenant de l'azote comme donneurs (1.4, 1.5, 1.7)
C12N 11/14 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support inorganique
B32B 3/14 - Produits stratifiés caractérisés essentiellement par le fait qu'une des couches comporte des discontinuités ou des rugosités externes ou internes, ou bien qu'une des couches est de forme générale non plane; Produits stratifiés caractérisés essentiellement par des particularismes de forme caractérisés par une couche discontinue, c. à d. soit continue et percée de trous, soit réellement constituée d'éléments individuels caractérisés par une couche de surface formée d'éléments individuels
C25B 11/073 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par le matériau Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique
[Problem] To provide a method for producing a nerve fascicle, the method comprising efficiently elongating an axon of a nerve cell. [Solution] Nerve cells are cultured in the presence of feeder cells including at least one kind of cell selected from among angiogenic cells, perivascular cells, and oligodendrocytes.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61L 27/40 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
A61L 27/58 - Matériaux au moins partiellement résorbables par le corps
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
77.
CANCER CELL DIAGNOSIS METHOD BASED ON SCAN CANTILEVER METHOD, DEVICE FOR ANALYZING DISTRIBUTION OF ELASTICITY CHARACTERISTICS OF SUBJECT CELLS, AND PROGRAM FOR CAUSING COMPUTER TO EXECUTE ANALYSIS OF DISTRIBUTION OF ELASTICITY CHARACTERISTICS OF SUBJECT CELLS
The present invention includes: a step in which an actual measurement value, that is obtained when a probe (24) of an atomic force microscope is pressed against a surface of a subject cell (3) and that associates a cell deformation quantity and a pressing force of the probe (24), is acquired together with measurement position coordinates of the subject cell (3) contacted by the probe (24), the measurement position coordinates of the subject cell (3) being disposed on a scan line so as to include an upper layer of a nucleus of the subject cell (3) and an area around the nucleus. The present invention also includes: a step in which, using a shape parameter determined in accordance with the shape of the tip of the probe (24) and a model formula that represents a relationship between the cell deformation quantity (d) and the pressing force (F) of the probe (24), a stress distribution of the subject cell (3) is computed; and a step in which a determination is made as to whether the stress distribution of the subject cell (3) calculated using the shape parameter is in a range within which the subject cell (3) is determined to be a normal cell.
The present invention addresses the problem of providing a new argan extract having a hair growth promotion effect. The present invention provides an argan extract manufacturing method including a step for performing extraction from argan seed kernel oil press residue or argan seed kernels by using a solvent containing an organic solvent, wherein the organic solvent concentration in the solvent is more than 20 wt.% and 100 wt.% or less.
The present invention makes it possible to easily estimate a stage of sleep. This sleep estimation device comprises: a first acquisition unit for acquiring blood flow data; a generation unit for generating a frequency spectrum of the blood flow data by performing frequency analysis processing with respect to the blood flow data; and a first determination unit for determining a sleep stage of a subject on the basis of the generated frequency spectrum.
A first inference unit (331) uses a first trained model (321) to infer command information at a first unit time. A second inference unit (332) uses a second trained model (322) to infer command information at a second unit time that is shorter than the first unit time from information that corresonds to command information derived by means of the first trained model (321). An operation control unit (333) uses the command information inferred by the second inference unit (332) to operate a control target device (10B).
B25J 3/00 - Manipulateurs de type à commande asservie, c. à d. manipulateurs dans lesquels l'unité de commande et l'unité commandée exécutent des mouvements correspondants dans l'espace
An image generating device according to the present invention includes: a tomographic-image acquisition unit that acquires an OCTA tomographic image in which the distribution of the blood flow of a subject is captured; an optical attenuation acquisition unit that acquires the optical attenuation of measurement light radiated on the subject in the layer direction of the tomographic image; and an image generating unit that generates an optical attenuation/blood-flow distribution image, which shows the distribution of the optical attenuation, on the basis of the acquired OCTA tomographic image and the optical attenuation.
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
82.
PARAMYLON-BASED RESIN, MOLDING MATERIAL, MOLDED BODY, AND PRODUCTION METHOD FOR PARAMYLON-BASED RESIN
C08L 5/00 - Compositions contenant des polysaccharides ou leurs dérivés non prévus dans les groupes ou
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes ; Leurs dérivés
83.
DISEASE CONDITION DETERMINATION DEVICE, DISEASE CONDITION DETERMINATION METHOD, PROGRAM FOR DISEASE CONDITION DETERMINATION DEVICE, AND DISEASE CONDITION DETERMINATION SYSTEM
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Komine Hidehiko
Kitazaki Satoshi
Akamatsu Motoyuki
Ishii Kei
Tsurushima Hideo
Shino Motoki
Abrégé
Provided are a disease condition determination device, a disease condition determination method, a program for a disease condition determination device, and a disease condition determination system which can determine the condition of epilepsy. Sight line data which indicate the position of a sight line of a subject T as measured when the subject T drives a vehicle V is acquired (S11), then driving characteristic data which indicate a driving characteristic of the subject T on the vehicle V is acquired (S10), and then the condition of epilepsy in the subject T is determined in accordance with the relationship between the sight line data and the driving characteristic data (S18).
G08G 1/13 - Systèmes de commande du trafic pour véhicules routiers indiquant la position de véhicules, p.ex. de véhicules à horaire déterminé à une station centrale l'indicateur étant sous la forme d'une carte
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
A61B 3/113 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
84.
MEASUREMENT SIGNAL PROCESSING DEVICE, MEASUREMENT SIGNAL PROCESSING METHOD, AND PROGRAM
In the present invention, a model learning unit defines, for each learning set that contains a measurement signal and at least one type of prescribed characteristic value indicative of a characteristic of the measurement signal as a target value, a model parameter used to calculate an estimate value obtained by performing a calculation on the measurement signal using a prescribed mathematical model so that the difference between the estimate value and the target value becomes small, defines a characteristic value set, which is a set of multiple types of characteristic values indicative of characteristics of the measurement signal including the target value, such that each type of the target value becomes common between a plurality of characteristic value sets, and generates, for each of the characteristic sets, the learning set that contains the target value and a measurement signal having the characteristics represented by the aforementioned multiple types of characteristic values.
Provided is a mobility assistance device capable of traversing a step in a stable manner without compromising mobility on level ground. This mobility assistance device comprises: front wheels; rear wheels; drive wheels disposed between the front wheels and the rear wheels; first links connected to the front wheels; second links connecting the drive wheels and the rear wheels; a rotary joint connecting the first links and the second links at a first position; and a first elastic member connecting the first links and the second links at a second position different from the first position.
A61G 5/06 - Fauteuils ou moyens de transport personnels spécialement adaptés pour des personnes handicapées, p.ex. fauteuils roulants avec dispositions pour franchir les obstacles, p.ex. pour monter les escaliers
This multi-viewpoint video filming device for surgical operations avoids shielding of illumination by the head and body of an operator and reflection of the head in a video, by disposing, in a space between the top of the head of the operator and an affected area, surgery filming illumination equipment attached to a housing having a finite-length curved shape, such as a hollow ring shape or an arc shape, the housing being devised such that a plurality of cameras and a plurality of illumination instruments are not obstacles to the visual field and work of the operator. Said multi-viewpoint video filming device enables surgery assistance/recording of surgery under direct vision through multi-viewpoint video by being provided with a function for inferring contexts of the plurality of cameras and adding a video information processing function for selecting a camera video in which there is little reflection of the hand of the operator or the surgical instrument in the image.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Endo Hirotoshi
Suzuki Iwane
Shiraiwa Yoshihiro
Maseda Hideaki
Abrégé
It was discovered that, by introducing into a cell a single strand DNA having a base sequence homologous to the base sequence of a target DNA region, it is possible to modify the methylated state of genomic DNA around the target DNA and suppress gene expression.
The purpose of the present invention is to develop a medicinal ingredient which can be ingested on a daily basis, has no adverse side effect, is highly safe, is relatively inexpensive and has an anti-psychiatric disease effect, and to provide an anti-depressant agent or a food or beverage which contains the medicinal ingredient. Provided are an anti-psychiatric disease agent and a food or beverage, each of which contains, as an active ingredient, a neuronal cell death inhibitor comprising an alga body of an alga belonging to the order Chlorellales which is cultured for a predetermined time period under strong light stress having a specific light intensity or an extract from the alga body.
This trained model generation program causes a computer to implement: a learning execution function for inputting, to a machine learning device, first input image data indicating a first input image generated by a first reconstruction method using compressed sensing, and second input image data indicating a second input image generated by a second reconstruction method that is different from the first reconstruction method and is an analytical reconstruction method, and causing the machine learning device to execute machine learning and generate a trained model; and a trained model acquisition function for acquiring trained model data indicating the trained model. Input image data indicating an input image is inputted to the trained model, and a reconstructed image that has improved image quality is generated.
The problem addressed is to provide a novel substance that is derived from natural products and is useful in the regulation of neurological function. The present invention is a method for manufacturing a food substance or a medicinal substance that includes at least one selected from the group consisting of 3-o-caffeoylquinic acid, 5-o-caffeoylquinic acid, 3-o-feruloylquinic acid, and isoorientin, the method including the following step: a step in which a fraction including at least one selected from the group consisting of 3-o-caffeoylquinic acid, 5-o-caffeoylquinic acid, 3-o-feruloylquinic acid, and isoorientin is obtained from the crown portion of a sugarcane plant using a water-based solvent. This composition or the like can be used for any selected from the group consisting of: the promotion of neurogenesis by the protection of nerve cells from amyloid-β, an increase in the secretion of brain neurotransmitters, the promotion of the production of ATP in nerve cells, or the growth of neural stem cells; the treatment of dementia, including senile dementia, Alzheimer's disease, vascular dementia, post-traumatic dementia, dementia resulting from brain tumor, dementia resulting from chronic subdural hematoma, dementia resulting from normal pressure cerebral edema, postmeningitic hydrocephalus, and Parkinson's disease; the treatment of non-dementing cognitive impairment, including mild cognitive impairment (MCI) and reduced cognitive function resulting from aging; the improvement of learning disorders and the improvement of memory disorders; the improvement of learning capability and the improvement of memory capability; the treatment of memory loss; the treatment of cerebral infarction and peripheral nerve injury; the treatment of mental disorders, including attention deficit hyperactivity disorder (ADHD), depression, and bipolar disorder; the improvement of drive and motivation; and the improvement of disturbances of circadian rhythm.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A23L 5/00 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux
A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
A61K 31/216 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p.ex. bénactizyne, clofibrate
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
Provided is a method for producing satellite cells. The present invention uses a production method including (1) a step for performing an enzymatic treatment on a muscle, and (2) a step for combing the enzymatically-treated muscle by using a comb in a manner parallel to the direction of muscle fibers.
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
UNIVERSITY OF TSUKUBA (Japon)
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Mori Kensaku
Oda Masahiro
Oshika Tetsuro
Ueno Yuta
Yamaguchi Takefumi
Fukuoka Hideki
Abrégé
Provided are a diagnostic imaging assistance device, a diagnostic imaging assistance system and a diagnostic imaging assistance method with which it is possible to determine a state of a captured image of an anterior eye part by machine learning. A diagnostic imaging assistance system 10 comprises an image processing determination device 12 having: an image database 30 for storing a learning image PL of an anterior eye part and information relating to a state of the learning image PL; and a determination unit 36 for determining the state of a captured subject image P by carrying out machine learning on the basis of the image database 30. This configuration makes it possible to determine the state of the subject image P, which is a captured image of the anterior eye part of the subject, by machine learning.
DRUG FOR PREVENTING AND/OR TREATING IMMUNE-RELATED SIDE EFFECT, GENETICALLY MODIFIED NON-HUMAN ANIMAL, AND NON-HUMAN MODEL ANIMAL FOR IMMUNE-RELATED SIDE EFFECT
The present invention addresses the problem of providing a drug for preventing and/or treating an immune-related side effect caused by an anti-PD-1 antibody or an anti-PD-L1 antibody. The present invention also addresses the problem of providing a genetically modified non-human animal in which PD-1/PD-L1 signaling is inhibited in a tissue-specific and time-specific manner. The present invention further addresses the problem of providing a non-human model animal for an immune-related side effect caused by an anti-PD-1 antibody or an anti-PD-L1 antibody and a drug screening method and evaluation method using the same. This drug contains a substance for inhibiting IL-6 signaling and is used to prevent and/or treat an immune-related side effect caused by an anti-PD-1 antibody or an anti-PD-L1 antibody. The immune-related side effect is at least one selected from skin disorders, myasthenia gravis, myocarditis, myositis, rhabdomyolysis, type 1 diabetes, neuropathy, kidney disorders, arthritis, liver disorders, pneumonia, pancreatitis, thyroiditis, adrenalitis, functional hypothalamic disorders, and panhypopituitarism. This genetically modified non-human animal is engineered by introducing a mutation into the PD-1 gene or an expression regulatory region of the PD-1 gene in the genome so that the expression of the PD-1 gene is completely or partially suppressed or lost in a tissue-specific and/or time-specific manner. This non-human model animal for an immune-related side effect caused by an anti-PD-1 antibody or an anti-PD-L1 antibody is produced by administering an adjuvant to a genetically modified non-human animal in which the expression of the PD-1 gene is completely or partially suppressed or lost by introducing a mutation into the PD-1 gene or an expression regulatory region of the PD-1 gene in the genome.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p.ex. enzymes pancréatiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 5/00 - Médicaments pour le traitement des troubles du système endocrinien
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
94.
SEMICONDUCTOR ELEMENT AND MANUFACTURING METHOD THEREOF, THERMOELECTRIC CONVERSION DEVICE AND MANUFACTURING METHOD THEREOF
This semiconductor element (100) is provided with a substrate which has a glass transition temperature of less than or equal to 600°C, and an n-type semiconductor layer (102) which is formed on one surface (101a) of the substrate and which contains, at a concentration equivalent to the solid solubility limit, an elemental substance or a compound of a Group 14 element, and an n-type impurity element.
Provided is a mutant KLF protein capable of inducing reprogramming of somatic cells at higher efficiency than a KLF protein composed of the natural amino acid sequence. Also provided is a method for producing iPS cells efficiently using the mutant KLF protein. Provided is a mutant KLF protein including an amino acid substitution, or a peptide fragment thereof that includes the amino acid substitution.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07K 14/46 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
xyy) (n≥4, 0.001≤x/y≤0.999), in which the molar ratio of boron to hydrogen is 1:0.999 to 1:0.001, as calculated by thermal desorption spectroscopy and mass measurement before and after temperature rise, wherein: in X-ray photoelectron spectroscopy, peaks derived from B1s of boron appears at 187.5±1.0 eV and 191.2±1.0 eV to 193±1.0 eV; and in an infrared spectroscopy, a peak derived from B-H expansion and contraction vibration appears at 2400cm-1to 2600cm-1, and a peak derived from B-H-B expansion and contraction vibration appears at 1200 cm-1to 1800 cm-1.
C01B 6/00 - Hydrures de métaux; Monoborane ou diborane; Leurs complexes d'addition
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
97.
IMAGE PROCESSING DEVICE, IMAGE PROCESSING METHOD, AND PROGRAM
According to the present invention, an electric field estimation unit converts an optical coherence tomographic signal representing the state of a sample into a spatial frequency domain and generates electric field data indicating the electric field on a pupil surface corresponding to the reciprocal space of the sample, a mask unit acts on the electric field data with a mask indicating the distribution of the transmission characteristics of the electric field on the pupil surface and generates mask electric field data, and a conversion unit converts the mask electric field data into a spatial region to generate a mask optical coherence tomographic signal. The present embodiment may be any of an image processing apparatus, an image processing method, and a program.
According to the present invention: a phase gradient calculating unit calculates a phase gradient on a plane intersecting the light radiation direction of an optical coherence tomography signal representing the state of a specimen, for each sample point arranged on the plane; and for each of a plurality of routes from a starting point, which is a sample point of which the bulk phase error has been determined, to an end point, which is a sample point of which the bulk phase error has not been determined, a bulk phase error calculating unit integrates the phase gradient at each sample point along each route to calculate a route-specific phase error at the end point, and defines the bulk phase error at the end point by combining the route-specific phase errors between the plurality of routes.
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
99.
TWO DIMENSIONAL BOROHYDRIDE-CONTAINING SHEET MANUFACTURING METHOD, TWO DIMENSIONAL BOROHYDRIDE-CONTAINING SHEET COMPOSITION, AND METHOD FOR MANUFACTURING SAME
C01B 6/00 - Hydrures de métaux; Monoborane ou diborane; Leurs complexes d'addition
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
Provided is a method for evaluating biological tissue, the method making it possible to quantitatively evaluate dynamics of the biological tissue. The evaluation method according to the present embodiment comprises acquiring an optical coherence tomography (OCT) signal that indicates the state of biological tissue serving as a specimen, acquiring a signal value based on the OCT signal for each observation point in the specimen, and calculating a change-over-time characteristic value that indicates a characteristic of the signal value that changes over time during a prescribed period. The present embodiment makes it possible to also implement an evaluation device or a program.
brevets
